Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
China Medical System Holdings ( (HK:0867) ) has shared an announcement.
China Medical System Holdings has received approval from China’s National Medical Products Administration to begin clinical trials in healthy participants for its self-developed innovative drug CMS-D017, a novel small-molecule inhibitor of complement factor B aimed at treating complement-mediated kidney diseases. CMS-D017 has shown strong preclinical efficacy and safety and is being developed for a range of complement-driven conditions, including IgA nephropathy, idiopathic membranous nephropathy, lupus nephritis, C3 glomerulopathy and previously-approved indications such as paroxysmal nocturnal hemoglobinuria, with future plans to target age-related macular degeneration and myasthenia gravis. The company expects CMS-D017 to address significant unmet needs in kidney disease where current steroid and immunosuppressant therapies are limited, and, once marketed, the drug is expected to create strong synergies with existing kidney-related products Velphoro and Desidustat, strengthening the group’s competitive position and market reach in nephrology.
The most recent analyst rating on (HK:0867) stock is a Hold with a HK$14.50 price target. To see the full list of analyst forecasts on China Medical System Holdings stock, see the HK:0867 Stock Forecast page.
More about China Medical System Holdings
China Medical System Holdings is a pharmaceutical group focused on developing and commercialising innovative therapies, with a growing presence in nephrology. Its portfolio includes the marketed drug Velphoro for chronic kidney disease-related hyperphosphatemia and the new drug Desidustat for renal anaemia, which is under regulatory review, positioning the company as an emerging player in kidney disease treatment in China.
Average Trading Volume: 4,376,605
Technical Sentiment Signal: Buy
Current Market Cap: HK$34.23B
For an in-depth examination of 0867 stock, go to TipRanks’ Overview page.